Hero B, et al. - The genomic copy number profiles of tumors from children with neuroblastomas presenting with opsoclonus myoclonus syndrome (OMS) at the time of diagnosis was determined. It was observed that 52% of tumors exhibited a segmental chromosome alteration genomic profile, 36% exhibited a numerical chromosome alteration genomic profile, and 1 case presented with an atypical profile (12q amplicon). Therefore, analysis of an excellent oncologic outcome, even for those with an unfavorable genomic profile of neuroblastoma, validated the hypothesis that an immune response could be involved in tumor control in these patients with OMS.